ADMA Biologics Inc. (NASDAQ:ADMA) shares fell to a low of $1.9135 before closing at $2.09. Intraday shares traded counted 10.49 million, which was -292.76% lower than its 30-day average trading volume of 2.67M. ADMA’s previous close was $1.96 while the outstanding shares total 87.70M. The firm has a beta of 1.86. The stock’s Relative Strength Index (RSI) is 55.73, with weekly volatility at 6.46% and ATR at 0.12. The ADMA stock’s 52-week price range has touched low of $1.45 and a $4.65 high. The stock traded higher over the last trading session, gaining 6.63% on 12/08/20.
Investors have identified the Biotechnology company ADMA Biologics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $194.68 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
ADMA Biologics Inc. (ADMA) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 139.55 million total, with 16.47 million as their total liabilities.
ADMA were able to record -78.91 million as free cash flow during the Q3 2020 quarter of the year, this saw their quarterly net cash flow reduce by 32.92 million. In cash movements, the company had a total of -69.78 million as operating cash flow.
Potential earnings growth for ADMA Biologics Inc. (ADMA)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the Q3 2020 quarter of the year, ADMA Biologics Inc. recorded a total of 10.28 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 29.71% coming in sequential stages and their sales for the Q3 2020 quarter increasing by 24.21%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 11.86 million trying to sell their products during the last quarter, with the result yielding a gross income of -1.58 million. This allows shareholders to hold on to 87.70M with the recently reported earning now reading -0.19 cents per share. This is a figure that compared to analyst’s prediction for their Q3 2020 (-0.19 cents a share).
Having a look at the company’s valuation, the company is expected to record -0.54 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ADMA sounds very interesting.
Is the stock of ADMA attractive?
In related news, Director, DEMSKI MARTHA J bought 2,200 shares of the company’s stock in a transaction that recorded on Sep 11. The purchase was performed at an average price of 2.29, for a total value of 5,038. As the purchase deal closes, the Director, Grossman Jerrold B now bought 5,000 shares of the company’s stock, valued at 11,100. Also, EVP, CSO and CMO, Mond James bought 4,000 shares of the company’s stock in a deal that was recorded on Sep 08. The shares were cost at an average price of 2.20 per share, with a total market value of 8,800. Following this completion of disposal, the President and CEO, Grossman Adam S now holds 4,000 shares of the company’s stock, valued at 8,960. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.50%.